As Exelixis Reigns In Spending, It Looks To Offload Early-Stage Assets
This article was originally published in The Pink Sheet Daily
Executive Summary
Management elaborates on plans to scale down early discovery and drug development to focus resources on its three lead partnered drugs.
You may also be interested in...
Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results
In interim Phase II data, the unpartnered drug reverses bone lesions in metastatic prostate cancer patients.
Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results
In interim Phase II data, the unpartnered drug reverses bone lesions in metastatic prostate cancer patients.
Exelixis Stays The Course Under New Leadership of Michael Morrissey
As the R&D chief transitions to CEO, he sees no huge strategic shifts for Exelixis, though it "has had a tough six months."